Systematic Review: Anti-Inflammatory Effects of Psychedelics in Preclinical Models

Robust Anti-Inflammatory Effects of Psychedelics in Preclinical Models

A systematic review and meta-analysis published in September 2026 synthesizes the evidence for anti-inflammatory effects of serotonergic psychedelics, finding robust effects in preclinical in vitro and animal models, but inconclusive results in humans due to limited data (OpenAlex W7214592286). The review screened 9,195 studies and included 61 eligible studies: 24 in vitro, 30 non-human in vivo, and seven human studies. Most in vitro (19/24) and non-human in vivo (25/30) studies reported anti-inflammatory effects, particularly reductions in proinflammatory cytokines. The meta-analysis of 18 murine studies found a significant decrease in proinflammatory cytokines in inflammatory models (standardized mean difference [SMD] = -1.23, 95% CI [-1.54, -0.92]), but no significant effects in healthy animals. This provides strong preclinical evidence that serotonergic psychedelics modulate immune activity under inflammatory conditions.

Potential Mechanisms: Immunomodulation and Neuropsychiatric Disorders

Serotonergic psychedelics, such as psilocybin and LSD, may exert anti-inflammatory effects by modulating immune signaling pathways, including the downregulation of proinflammatory cytokines like TNF-α, IL-6, and IL-1β. These immunomodulatory properties could underlie some of the observed clinical benefits in neuropsychiatric disorders, where inflammation is increasingly recognized as a contributing factor. However, the review found that in healthy animal models, psychedelics did not significantly alter immune markers, suggesting that their effects may be context-dependent and most pronounced in the presence of baseline inflammation. This insight challenges the assumption that psychedelics have broad-spectrum anti-inflammatory effects and points toward a more nuanced, conditional mechanism of action.

Translational Gap: Human Evidence Remains Inconclusive

Despite promising preclinical findings, human data on the anti-inflammatory effects of psychedelics are sparse and mixed. Of the ten human trials identified, only three reported significant anti-inflammatory effects, and the four studies included in the meta-analysis were too few to yield precise or generalizable estimates. The small sample sizes, variability in study design, and heterogeneity in measured immune markers all contribute to the limited interpretability of the human data. This translational gap highlights a critical challenge for researchers and clinicians: robust preclinical effects do not guarantee similar outcomes in humans, especially given differences in immune system complexity and the multifactorial nature of neuropsychiatric disorders.

Policy and Research Implications: Caution and Rigor Required

The findings of this review have important implications for clinical trial design, regulatory policy, and the broader field of psychedelic medicine. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) will require robust, well-powered human trials demonstrating clear clinical benefit and mechanistic plausibility before approving psychedelics for indications involving immune modulation. Researchers designing future trials should incorporate standardized immune markers, stratify participants by baseline inflammation, and ensure adequate sample sizes to detect clinically meaningful effects. Notably, the review underscores the risk of over-extrapolating from animal models to human disease, a failure mode that has historically led to setbacks in drug development for neuroinflammation and psychiatric disorders.

Risks, Unknowns, and the Path Forward

Current evidence does not support the clinical use of psychedelics as anti-inflammatory agents in humans, and premature claims could expose patients and clinicians to unproven interventions. Potential risks include unforeseen immunological side effects, drug interactions, and the possibility that immunosuppression could be harmful in certain populations. The review also highlights the need for research into the long-term effects of repeated psychedelic exposure on immune function, a question largely unaddressed in existing studies. Moving forward, multidisciplinary collaborations between immunologists, neuroscientists, and clinical trialists will be essential to clarify the therapeutic potential and limitations of psychedelics in modulating human inflammation.

Conclusion: A Promising but Unproven Mechanism

Serotonergic psychedelics show consistent anti-inflammatory effects in preclinical models of inflammation, but the evidence in humans remains limited and inconclusive. The field faces a critical translational gap, and rigorous, well-designed clinical trials are needed before these compounds can be considered for immunomodulatory indications. Stakeholders across research, clinical, and regulatory domains should exercise caution, prioritize methodological rigor, and remain alert to both the promise and the pitfalls of translating preclinical findings into human therapies.

How we research / reviewed by Dr. Alex Morgan, PhD (Neuroimmunology), on 2026-09-29.